DK1187603T3 - Kombinationsterapi tl at bevirke vægttab og at behandle obesitet - Google Patents

Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Info

Publication number
DK1187603T3
DK1187603T3 DK00939884T DK00939884T DK1187603T3 DK 1187603 T3 DK1187603 T3 DK 1187603T3 DK 00939884 T DK00939884 T DK 00939884T DK 00939884 T DK00939884 T DK 00939884T DK 1187603 T3 DK1187603 T3 DK 1187603T3
Authority
DK
Denmark
Prior art keywords
weight loss
combination therapy
treat obesity
cause weight
phentermine
Prior art date
Application number
DK00939884T
Other languages
Danish (da)
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of DK1187603T3 publication Critical patent/DK1187603T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK00939884T 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet DK1187603T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09
PCT/US2000/016434 WO2000076493A1 (en) 1999-06-14 2000-06-14 Combination therapy for effecting weight loss and treating obesity

Publications (1)

Publication Number Publication Date
DK1187603T3 true DK1187603T3 (da) 2007-12-17

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00939884T DK1187603T3 (da) 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Country Status (10)

Country Link
EP (5) EP2305226B1 (de)
AT (1) ATE369126T1 (de)
AU (1) AU770068B2 (de)
CA (2) CA2686633A1 (de)
CY (1) CY1106974T1 (de)
DE (1) DE60035870T2 (de)
DK (1) DK1187603T3 (de)
ES (4) ES2542868T3 (de)
PT (1) PT1187603E (de)
WO (1) WO2000076493A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
NZ523531A (en) 2000-07-07 2005-07-29 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful for preventing the development of type II diabetes mellitus and syndrome X
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
MXPA03003870A (es) * 2000-10-30 2004-08-12 Johnson & Johnson Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
EP3173082A1 (de) 2002-05-17 2017-05-31 Duke University Verfahren zur behandlung von adipositas
MXPA05006203A (es) * 2002-12-13 2005-08-19 Cilag Ag Formulaciones estables de topiramato.
EP1617832B1 (de) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Zusammensetzungen zur beeinflussung des gewichtsverlusts
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EP2026790A2 (de) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
DK2089005T3 (da) * 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2010059586A1 (en) 2008-11-19 2010-05-27 Entrigue Surgical, Inc. Apparatus and methods for correcting nasal valve collapse
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
EP2961350B1 (de) 2013-02-27 2018-03-28 Spirox, Inc. Nasenimplantate und systeme
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
JP2017502659A (ja) 2013-12-05 2017-01-26 ジボダン エス エー 有機化合物
ES3013305T3 (en) 2014-08-26 2025-04-11 Stryker Corp Nasal implant
EP3352690B1 (de) 2015-09-25 2023-09-13 Spirox, Inc. Nasenimplantate
US12046341B2 (en) 2021-10-05 2024-07-23 Bradford Rabin Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
CY1106974T1 (el) 2012-09-26
EP2305226B1 (de) 2015-05-06
DE60035870T2 (de) 2008-05-08
EP2305226A1 (de) 2011-04-06
EP2308481A1 (de) 2011-04-13
ES2542868T3 (es) 2015-08-12
EP1187603B1 (de) 2007-08-08
EP2305228A1 (de) 2011-04-06
EP2305228B1 (de) 2015-05-06
CA2686633A1 (en) 2000-12-21
EP2308481B1 (de) 2015-05-06
ES2291215T3 (es) 2008-03-01
AU5489600A (en) 2001-01-02
CA2377330A1 (en) 2000-12-21
EP2305227B1 (de) 2015-05-06
PT1187603E (pt) 2007-11-16
CA2377330C (en) 2009-11-24
ES2542891T3 (es) 2015-08-12
ES2542892T3 (es) 2015-08-12
EP1187603A4 (de) 2004-02-11
EP2305227A1 (de) 2011-04-06
WO2000076493A1 (en) 2000-12-21
ATE369126T1 (de) 2007-08-15
DE60035870D1 (de) 2007-09-20
AU770068B2 (en) 2004-02-12
EP1187603A1 (de) 2002-03-20

Similar Documents

Publication Publication Date Title
DK1187603T3 (da) Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
HUP0303917A2 (hu) Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
PT1333887E (pt) Metodo de tratamento de desordens musculares
DK0841949T3 (da) Anvendelse af saccharid-konjugater
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
EP0824917A3 (de) Verwendung eines Serotonin 5-HT1F Agonists zur Herstellung eines Wirkstoffs für die Behandlung oder die Verbesserung des Schnupfens oder der allergischen Rhinitis
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
ATE306977T1 (de) Schaukel für behinderte
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
EP1825851A3 (de) Kombinationstherapie zur Gewichtsreduzierung und Fettleibigkeitsbehandlung
CY1109771T1 (el) Η χρηση της φορμοτερολης στην προφυλακτικη και/ή θεραπευτικη αντιμετωπιση της μυικης απωλειας και/ή του καχεκτικου συνδρομου τα οποια συνδεονται με τις καταβολικες συνθηκες ορισμενων παθησεων. οπως ο καρκινος, to aids, οι μολυνσεις, ο διαβητης και αλλες
NO995539D0 (no) Anvendelse av hepariner med lav molekylvekt for prevensjon og terapi av cerebrale ödemer
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
BR0012318A (pt) Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
CO5590922A2 (es) Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta
EA200301127A1 (ru) Способы лечения опосредованных прионами заболеваний у млекопитающих, предусматривающие введение разобщающего агента, такого как гуанидин, мочевина или йодид калия